Valuation: Agios Pharmaceuticals, Inc.

Market Cap 2.23B 1.95B 1.8B 1.67B 3.17B 213B 3.22B 21.56B 8.38B 105B 8.39B 8.21B 360B P/E 2026 *
-6.03x
P/E 2027 * -7.88x
Enterprise Value 1.92B 1.68B 1.54B 1.43B 2.72B 182B 2.76B 18.48B 7.18B 89.68B 7.19B 7.04B 309B EV / Sales 2026 *
15.7x
EV / Sales 2027 * 8.17x
Free-Float
77.7%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Agios Pharmaceuticals, Inc.

1 day+1.35%
1 week-0.84%
Current month+1.27%
1 month+32.84%
3 months+6.76%
6 months+36.90%
Current year+38.06%
1 week 36.35
Extreme 36.35
38.38
1 month 26.89
Extreme 26.89
38.38
Current year 24.29
Extreme 24.29
38.38
1 year 22.24
Extreme 22.24
46
3 years 19.8
Extreme 19.795
62.58
5 years 16.75
Extreme 16.75
62.58
10 years 16.75
Extreme 16.75
99.82
Manager TitleAgeSince
Chief Executive Officer 57 2022-08-07
Director of Finance/CFO 51 2022-09-25
Chief Tech/Sci/R&D Officer 47 2021-08-31
Director TitleAgeSince
Director/Board Member 66 2014-12-08
Director/Board Member 73 2015-06-22
Director/Board Member 73 2017-05-26
Date Insider Type Main position Quantity % Market Cap.
06-30Fiscal year

Chief Technology Officer

20,757 0.0349%
06-17Fiscal year

Executive/Senior Manager

-6,000 0.0101%
06-17Fiscal year

Chief Financial Officer

-6,000 0.0101%
Change 5-day change 1-year change 3-year change Capi.($)
+1.35%-0.84%+4.19%+36.80% 2.23B
-0.17%+5.60%+78.02%+135.76% 59.1B
+2.32%+5.03%+75.26%+92.31% 55.19B
+3.86%+6.93%-11.32%-10.57% 24.67B
+4.30%+7.95%+14.11%+440.44% 24.19B
+0.96%+7.48%+51.38%-0.73% 19.69B
+0.01%+9.16%+43.43%-27.73% 17.56B
0.00%+20.78%+186.15%+347.42% 16.22B
+5.31%+20.29%+48.69% - 14.84B
+3.50%+1.97%+21.02%+193.33% 14.04B
Average +2.11%+8.09%+51.09%+134.11% 24.77B
Weighted average by Cap. +1.87%+6.45%+59.13%+135.01%

Financials

2026 *2027 *
Net sales 122M 107M 97.94M 91.29M 173M 11.61B 176M 1.18B 457M 5.71B 458M 448M 19.66B 257M 224M 206M 192M 365M 24.45B 370M 2.48B 963M 12.02B 964M 943M 41.41B
Net income -370M -323M -297M -277M -525M -35.18B -533M -3.56B -1.39B -17.29B -1.39B -1.36B -59.59B -293M -256M -235M -219M -416M -27.9B -422M -2.83B -1.1B -13.71B -1.1B -1.08B -47.26B
Net Debt -319M -279M -256M -239M -453M -30.35B -460M -3.07B -1.2B -14.92B -1.2B -1.17B -51.41B -136M -119M -110M -102M -194M -12.99B -197M -1.32B -512M -6.39B -512M -501M -22.01B
Logo Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
Employees
540
Date Price Change Volume
26-07-02 US$37.58 +1.35% 791,174
26-07-01 US$37.08 -0.08% 1,133,166
26-06-30 US$37.11 -2.44% 987,909
26-06-29 US$38.04 +0.37% 771,616
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
37.58USD
Average target price
40.75USD
Spread / Average Target
+8.44%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGIO Stock